Wayne Landers

Christ Follower. Bible Reader. Pill Pusher. Professor. Hog Fan. Husband to @amyleewit.Proud Dad to Mady Belle.

[Todd Yakoubian @ToddYakoubian]

Severe Thunderstorm Warning is in effect until Aug 22 8:00PM for Pulaski, Faulkner, Perry, Saline. Stay with the Arkansas Storm Team for the newest information. #ARWX #ARStormTeam

[Wayne Landers @WayneLanders]

@ToddYakoubian @Paul_The_Wxguru

[Wayne Landers @WayneLanders]

Weather coming into Conway. Photo taken from Round Mountain

[Little Rock Christian Academy @lrcawarriors]

Jubilee. A time for rest, return, and redemption. Fulfilled in Jesus. Happy 50th, Little Rock Christian!

#warriorville #lrca #littlerockchristianacademy #50years #jubilee

[Wayne Landers @WayneLanders]

@bwyatt1 @Delta Thanks! I did 👊

[Wayne Landers @WayneLanders]

@Delta I am on flight DL 1579 from MIA to ATL. We were delayed over an hour. Is there a way for my connection flight DL 3025 to LIT to hold until I can get there?

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: BeOne Medicines announced today that the European Commission has approved our immunotherapy in combination with chemotherapy as a first-line treatment for adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).

NPC is a rare cancer in which malignant cells form in the nasopharynx, the upper part of the throat located behind the nose. Despite advances in cancer care, major unmet needs remain due to late diagnosis, limited treatment options for recurrent/metastatic cases, and regional disparities in access to therapies. We're committed to addressing these gaps—supporting research, access, and innovation to bring hope to patients and families affected by NPC.

https://t.co/zYNP8Qt428

#BeOneMedicines #NasopharyngealCancer
#Oncology #LungCancer

[BeOne Medicines @BeOneMedicines]

#Cancer is smart. We must be smarter. Learn how we’re prioritizing quality, speed and efficiency in our R&D efforts to meet the urgent needs of patients worldwide: https://t.co/UGPVISnnK9

#PatientsFirst #CancerHasNoBorders #Oncology

[BeOne Medicines @BeOneMedicines]

At BeOne Medicines, we’re proud to be a team of individuals – diverse, unique, and united by a shared mission: to change the outlook of cancer. BeOne reflects not just a brand, but the passion and purpose that unify and define us. Every breakthrough, every bold step, is powered by our people.

If you’re onsite at #ASCO25, stop by Booth 30071 to meet the people behind the mission and discover what it truly means to #BeOneAgainstCancer.

#TeamBeOne #BeOneAtASCO

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: At #ASCO25, we’re unveiling new data from Arm C and D of our Phase 3 SEQUOIA study evaluating our BTK inhibitor in patients with treatment-naïve chronic lymphocytic leukemia (#CLL). These findings reinforce the potential of our BTK inhibitor as a frontline option in CLL/SLL.

To learn more, read our latest press release: https://t.co/ymg8QYfvor

#CancerResearch

[BeOne Medicines @BeOneMedicines]

We’re proud to announce our new name—BeOne Medicines—and our redomiciliation to Switzerland are now officially in effect. This marks a major milestone in our evolution as a company.

BeOne is more than just a name change. It reflects who we are today as a leading global oncology company—and our bold ambition to redefine the future of cancer care. With a powerful oncology portfolio, a pioneering approach to clinical development, and expanded global manufacturing and commercial capabilities, we’re well-positioned to deliver transformative treatments to patients worldwide.

As one, we’re uniting patients, families, scientists, physicians, governments, and other oncology public health stakeholders around the world in our shared mission against cancer.

Read more in our press release: https://t.co/QqJR6gsOPj

#BeOneAgainstCancer #CancerCare #Oncology

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: The European Commission has granted marketing authorization for our immunotherapy in combination with certain chemotherapies as a first-line treatment for extensive-stage small cell lung cancer (#SCLC).

With approximately 70% of SCLC patients diagnosed with extensive-stage disease, treatment options have long been limited. The European Commission's approval of this treatment for eligible patients facing one of the most challenging forms of lung cancer reflects our dedication to advancing the science in areas of high unmet need.
#Oncology #LungCancer

[BeOne Medicines @BeOneMedicines]

The @US_FDA has approved new dosing options for our PD-1 inhibitor in both first- and second-line esophageal squamous cell carcinoma (#ESCC) and first-line gastric cancer, providing more flexibility for pairing our immunotherapy with the most common chemotherapy regimens.

This approval reinforces our dedication to patients in the U.S. living with upper GI cancers—helping to expand access to personalized treatment approaches and supporting providers in delivering care that fits the unique needs of each patient.

[BeOne Medicines @BeOneMedicines]

Excited to welcome Melika Davis, SVP & Global Head of Clinical Operations, to the podcast! She’s giving us an inside look at how we manage clinical trials worldwide — from strategy to execution. Don’t miss this behind-the-scenes conversation! Tune in now:

YouTube: https://t.co/SlQ8SqY5dy
Apple: https://t.co/4b8g6EEOHZ

#ClinicalTrials #Podcast #HealthcareInnovation

[BeOne Medicines @BeOneMedicines]

Our investigational BTK-targeted CDAC, BGB-16673, attacks a well-validated target with an entirely new approach. This is just one of our pipeline programs with the potential to transform treatment paradigms. Visit https://t.co/8gt6MPPTiA to learn more about our degrader platform.

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: Today we announced the U.S. FDA has approved our PD-1 inhibitor, in combination with chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1). Gastric cancer is the world’s 5th most common cancer, and in the U.S. approximately 27,000 patients are diagnosed each year. This approval marks a significant step forward in our mission to deliver transformative therapies to patients with cancer.
#stomachcancer https://t.co/pOp4pU6qiq

[Aaron Torres @Aaron_Torres]

Arkansas administration thought it was doing itself a favor bringing back Sam Pittman for another season.

Pretty sure all it did was set them back five in the process 🤦‍♂️🤦‍♂️

[Wayne Landers @WayneLanders]

@TyroneBroden 5

[Wayne Landers @WayneLanders]

Incredible views in Conway!